Literature DB >> 29721816

Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis.

Khalaf Kridin1, Arnon D Cohen2,3, Kyle T Amber4.   

Abstract

BACKGROUND: There is little consensus regarding the prevalence and distribution of underlying systemic diseases among patients with pyoderma gangrenosum.
OBJECTIVE: The objective of this study was to synthesize existing data on the prevalence of associated systemic diseases in patients with pyoderma gangrenosum.
METHODS: We performed a systematic review and meta-analysis of observational studies in MEDLINE, EMBASE, and Scopus (1823-2017). The quality of evidence was assessed using a modified Newcastle-Ottawa Scale. A meta-analysis was performed using random-effects models to estimate pooled prevalence rates with 95% confidence intervals.
RESULTS: Twenty-one eligible studies comprising 2611 patients with pyoderma gangrenosum were included in the quantitative synthesis. The overall random-effects pooled prevalence of associated systemic diseases was 56.8% (95% confidence interval 45.5-67.4). The leading underlying disease was inflammatory bowel disease (17.6%; 95% confidence interval 13.0-22.7), followed by arthritis (12.8%; 95% confidence interval 9.2-16.9), hematological malignancies (8.9%; 95% confidence interval 6.5-11.6), and solid malignancies (7.4%; 95% confidence interval 5.8-9.1). In 16.3% (95% confidence interval 7.7-27.1) of cases, the onset of pyoderma gangrenosum was attributed to the pathergy phenomenon.
CONCLUSIONS: More than half of patients with pyoderma gangrenosum present with a relevant underlying disease. Inflammatory bowel disease and arthritis are the most frequently associated diseases. Relative to the reported literature, the pooled prevalence of arthritis and hematological malignancies is lower, while the pooled prevalence of solid malignancies is higher. Owing to the high level of heterogeneity among most of the comparisons, results should be interpreted with caution.

Entities:  

Mesh:

Year:  2018        PMID: 29721816     DOI: 10.1007/s40257-018-0356-7

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  12 in total

1.  Necrotising fasciitis or pyoderma gangrenosum: A fatal dilemma.

Authors:  Cenk Demirdover; Alper Geyik; Haluk Vayvada
Journal:  Int Wound J       Date:  2019-08-16       Impact factor: 3.315

2.  Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study.

Authors:  Khalaf Kridin; Giovanni Damiani; Arnon D Cohen
Journal:  Clin Rheumatol       Date:  2020-07-01       Impact factor: 2.980

3.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

4.  Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.

Authors:  Erika Sawka; Allison Zhou; Emile Latour; Marcia Friedman; Alex G Ortega-Loayza
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 3.650

5.  Pyoderma Gangrenosum: A Retrospective Study of Clinical Charac-teristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose.

Authors:  Louise Schøsler; Karsten Fogh; Rikke Bech
Journal:  Acta Derm Venereol       Date:  2021-04-15       Impact factor: 3.875

6.  Pyoderma Gangrenosum Revealing Myeloid Activation of Fanconi Anaemia: Two Case Reports.

Authors:  Alexandra Mokrzycki; Coralie Lheure; Nathalie Franck; Gérard Socié; Clémence Mauppin; Flore Sicre de Fontbrune; Régis Peffault de Latour; Clémence Lepelletier; Adèle de Masson; Maxime Battistella; Guy Leverger; Pierre Sohier; Jean-David Bouaziz; Nicolas Dupin
Journal:  Acta Derm Venereol       Date:  2020-12-01       Impact factor: 3.875

7.  Scrotal Pyoderma Gangrenosum Associated with Evans Syndrome.

Authors:  Deng-Ho Yang; Meng-Yin Yang
Journal:  J Clin Med       Date:  2018-08-22       Impact factor: 4.241

8.  Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia.

Authors:  Tyler A Hooton; Josiah F Hanson; John E Olerud
Journal:  JAAD Case Rep       Date:  2021-01-12

9.  Concurrent Scleredema and Pyoderma Gangrenosum: Case Report and Review of Comorbid Conditions.

Authors:  Joanne S Jacob; Philip R Cohen
Journal:  Cureus       Date:  2020-12-20

10.  Chronic renal comorbidities in pyoderma gangrenosum: a retrospective cohort study.

Authors:  Khalaf Kridin; Arieh Solomon; Rimma Laufer Britva; Dana Tzur Bitan; Arnon D Cohen
Journal:  Immunol Res       Date:  2021-04-22       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.